{"id":296086,"date":"2026-01-21T16:43:06","date_gmt":"2026-01-21T16:43:06","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/296086\/"},"modified":"2026-01-21T16:43:06","modified_gmt":"2026-01-21T16:43:06","slug":"jj-wants-to-be-the-leader-in-the-cancer-fight-its-strategy-is-starting-to-pay-off-as-oncology-sales-top-25-billion-in-2025","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/296086\/","title":{"rendered":"J&J wants to be the leader in the cancer fight. Its strategy is starting to pay off as oncology sales top $25 billion in 2025."},"content":{"rendered":"

Last Updated: Jan. 21, 2026 at 10:14\u202fa.m. ET
First Published: Jan. 21, 2026 at 7:26\u202fa.m. ET<\/p>\n

Johnson & Johnson had another strong quarter, driven by revenue growth of two important cancer drugs, but it also reported lower-than-expected net profit.<\/p>\n

J&J reported steady revenue performance in the fourth quarter as its new strategy comes into play. The company is making major changes to its business model under Chief Executive Joaquin Duato, in part to offset declining sales of autoimmune drug Stelara, which lost patent protection. That includes spinning off<\/a> its orthopedic device business, which makes up about 10% of its total revenue, by mid-2027 and its narrowed focus on six key areas like oncology. <\/p>\n","protected":false},"excerpt":{"rendered":"Last Updated: Jan. 21, 2026 at 10:14\u202fa.m. ETFirst Published: Jan. 21, 2026 at 7:26\u202fa.m. ET Johnson & Johnson…\n","protected":false},"author":2,"featured_media":296087,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[275],"tags":[41573,110,41570,13782,41565,6738,18,35567,41571,14480,41579,3334,135,475,474,19,41586,146998,19006,17,139787,146999,2994,14965,3865,114888,2900,9436,44285,12896,26243],"class_list":{"0":"post-296086","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-ce-industry-news-filter","9":"tag-cancer","10":"tag-content-types","11":"tag-corporate","12":"tag-corporate-industrial-news","13":"tag-earnings","14":"tag-eire","15":"tag-equity-markets","16":"tag-factiva-filters","17":"tag-financial-performance","18":"tag-gcapi","19":"tag-general-news","20":"tag-health","21":"tag-health-care","22":"tag-healthcare","23":"tag-ie","24":"tag-industrial-news","25":"tag-industrial-property-rights","26":"tag-intellectual-property-rights","27":"tag-ireland","28":"tag-jnj","29":"tag-joaquin-duato","30":"tag-johnson-johnson","31":"tag-manufacturing","32":"tag-medical-conditions","33":"tag-patents","34":"tag-pharmaceuticals","35":"tag-political","36":"tag-political-general-news","37":"tag-sales-figures","38":"tag-synd"},"share_on_mastodon":{"url":"","error":"Validation failed: Text character limit of 500 exceeded"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/296086","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=296086"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/296086\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/296087"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=296086"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=296086"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=296086"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}